ArticleHepatology (Baltimore, Md.)2021
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 237 citations in OpenAlex.
- Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease.Lipids in health and disease · 2025Pooled it
- Genome-Wide Association Study of NAFLD Using Electronic Health Records.Hepatology communications · 2022Pooled it
- Long-term ambient benzene exposure increases incident NAFLD risk through accelerated biological aging.iScience · 2026Article
- Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study.Hepatology international · 2026Article
- Changes in Muscle Mass and the Risk of Liver-Related Events: A Prospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.Hepatology international · 2026Review
- Article
- The rate of and risk factors for falls among patients with cirrhosis: A multicenter study.Hepatology communications · 2026Article
- Social and Functional Risk Patterns and All-Cause Mortality Among US Adults with Chronic Liver Disease.Medical sciences (Basel, Switzerland) · 2026Article
- Epidemiology of Patients With Chronic Liver Disease Presenting to Emergency Departments in Australia.Emergency medicine Australasia : EMA · 2026Article
- Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.Alimentary pharmacology & therapeutics · 2026Article
- Cardiometabolic comorbidity and health outcomes of persons with metabolic dysfunction-associated steatotic liver disease (MASLD) in Ontario, Canada.Canadian liver journal · 2026Article
- Plasma proteomics framework predicts metabolic dysfunction-associated steatotic liver disease up to 16 years before onset.Nature aging · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome: Development of anJMIR diabetes · 2026Article
- Association between metabolic signatures of predicted VAT mass and risk of MASLD and other chronic liver diseases.International journal of obesity (2005) · 2026Article
- Implications of Expanded Advanced Fibrosis Screening Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Association of total and regional fat-to-muscle ratio with the risk of metabolic dysfunction-associated fatty liver disease and other chronic liver diseases.Hepatology international · 2026Article
- Association of metabolic vulnerability index with various chronic liver diseases and mortality: a large prospective cohort study.BMC gastroenterology · 2026Article
- Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.Nutrition & metabolism · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 19 institutions in 13 countries.
Funding
Abstract
BACKGROUND AND
aimsElectronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in NAFLD, where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Diseases (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues. APPROACH AND
resultsResearchers with an interest in EHR-based NAFLD research were invited to collectively define which administrative codes are most appropriate for documenting exposures and outcomes. We used a modified Delphi approach to reach consensus on several commonly encountered methodological challenges in the field. After two rounds of revision, a high level of agreement (>67%) was reached on all items considered. Full consensus was achieved on a comprehensive list of administrative codes to be considered for inclusion and exclusion criteria in defining exposures and outcomes in EHR-based NAFLD research. We also provide suggestions on how to approach commonly encountered methodological issues and identify areas for future research.
conclusionsThis expert panel consensus statement can help harmonize and improve generalizability of EHR-based NAFLD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.